Purpose of Technology

Sublingual immunotherapy involves the administration of a diluted dose of an allergen under the tongue, which allows the material to contact the oral mucosa. Sublingual immunotherapy has been investigated in patients with allergic rhinitis and/or asthma associated with sensitivity to seasonal allergens, and to allergens such as dust mites, mold, pet dander, or nuts. In contrast to standard immunotherapy, which requires subcutaneous injections, sublingual therapy may offer a lower risk of serious side effects, and may be more comfortable and acceptable to many patients.

Questions addressed in this report include:

• Does sublingual immunotherapy reduce the symptoms of rhinitis and asthma associated with inhaled allergens such as pollen, grass, or dust mites?
• Is sublingual immunotherapy safe?
• Have definitive patient selection criteria been established for sublingual immunotherapy?

These questions provide a framework for review and synthesis of the best available evidence, which is presented in this report, along with the Hayes Ratings for the technology. This report also provides background information about the condition being treated, a description of the technology, and the context for development of the technology. Other key elements addressed in the report include the regulatory status; applicable Medicare and commercial payer coverage policies; relevant ICD-9 and ICD-10 diagnosis codes; cost and cost effectiveness; credentialing; hospital length of stay; need for large case management; and ongoing and future clinical trials of the technology.

Posted in Directory Reports
This entry was posted on Thursday, October 20th, 2011 at 8:32 am.